The GLP-1 Pathway
biased agonism at the GLP-1 receptor -- why tirzepatide signals differently than semaglutide
Same Receptor, Different Signal
Tirzepatide activates the GLP-1 receptor, but it does so differently than selective GLP-1 agonists like semaglutide. The concept is called biased agonism: tirzepatide preferentially triggers certain intracellular signaling pathways over others at the GLP-1 receptor, which may explain differences in tolerability and efficacy. This unit breaks down the GLP-1 signaling cascade, explains what biased agonism means at a molecular level, and connects it to clinical effects on appetite and gastric emptying.
GLP-1 Receptor Bias
Compare how tirzepatide and semaglutide activate different signaling pathways at the same receptor.